Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases

* Participants with a diagnosis of rheumatoid arthritis, ankylosing spondylitis or plaque psoriasis * Decision to initiate Humira® treatment in accordance with routine medical practice and in compliance with eligibility for adalimumab based on the local label * Prior to any study-specific procedures, participant has voluntarily signed the authorization (or informed consent where applicable) to disclose and use anonymized personal health information after participate in this research.

* Inadequate response to previous standard treatment with anti-tumor necrosis factor (TNF) biological agent according to the physician's clinical judgment. * Participant has been treated with adalimumab within 70 days (five half-lives) prior to the Baseline Visit. * Participants discontinued due to adverse drug reaction of previous adalimumab treatment. * Participants who fulfill any of the contraindications as per adalimumab label in China. * Participants, who in the clinician's view, may not be able to comply with the study requirements.